NEJM Pre-Submission Checklist: Is Your Paper Ready for the World's Most Cited Medical Journal?
NEJM desk rejects ~90% of submissions within 2 weeks. Before you submit, verify these 12 items covering clinical impact, trial registration, statistical rigor, and what editors screen for first.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Readiness scan
Before you submit to New England Journal of Medicine, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
New England Journal of Medicine at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 78.5 puts New England Journal of Medicine in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~<5% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: New England Journal of Medicine takes ~21 day. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
Quick answer: NEJM receives thousands of submissions per year and desk rejects roughly 90% of them within two weeks. Of the ~10% that reach peer review, another 50% are rejected after review. The overall acceptance rate is under 5%. These numbers are not meant to discourage you. They are meant to emphasize that a submission to NEJM without thorough preparation is almost certainly a waste of 2 to 4 weeks. This checklist covers what NEJM editors actually evaluate so you can identify problems before they become a 2-week desk rejection.
If you are still deciding whether this is the right target, start with the NEJM journal hub before you format the paper around NEJM-specific requirements.
Check your NEJM readiness in 1-2 minutes with the free scan.
Clinical impact
1. Does the finding change how physicians care for patients?
This is NEJM's threshold question. Not "is this scientifically interesting?" but "will doctors treat patients differently after reading this?" Papers that clear the desk tend to be large, well-designed randomized trials with definitive results on clinically important endpoints. The finding must be large enough in magnitude to affect real treatment decisions, not just statistically significant.
2. Is the clinical implication stated in the first paragraph of the abstract?
NEJM editors scan hundreds of abstracts. If the clinical consequence is buried in the last sentence, the first impression is weaker. The abstract should open with the clinical problem and state the practice-changing finding within the first three sentences.
3. Would this finding be discussed at hospital grand rounds within a week of publication?
This is an informal but useful test. If the result would generate immediate discussion among clinicians across specialties, it has NEJM-level impact. If it would mainly interest researchers in one specialty, a specialty journal is a better target.
Study design and evidence
4. Is the study design strong enough for the claims?
NEJM strongly favors large randomized controlled trials. Observational studies are published but face higher scrutiny. Post-hoc analyses of trials designed to answer different questions are typically desk rejected. The design must be pre-specified and appropriate for the primary outcome.
5. Is the trial registered before enrollment began?
NEJM requires prospective trial registration in an approved registry (ClinicalTrials.gov, WHO ICTRP) before the first participant is enrolled. Manuscripts describing unregistered trials are returned without review. The registration number must appear in the abstract.
6. Does the registered primary outcome match the manuscript?
Editors check. If the primary outcome in the published paper differs from the registered primary outcome, this raises selective reporting concerns. Any protocol amendments must be documented and justified.
Statistical rigor
7. Will the analysis survive independent statistical review?
NEJM sends papers that advance to revision for independent statistical review by one of five statistical consultants. This review is rigorous and evaluates sample size justification, analytical methods, missing data handling, multiplicity corrections, and subgroup analysis validity. Many authors are not prepared for this level of statistical scrutiny.
Prepare by ensuring: sample size is justified with a power analysis, the primary analysis is pre-specified, sensitivity analyses address missing data, subgroup analyses are identified as pre-specified or exploratory, and confidence intervals are reported alongside p-values.
8. Are the results reported with appropriate precision?
Exact p-values (not just "p<0.05"). Confidence intervals for all primary outcomes. Effect sizes, not just significance. Hazard ratios, odds ratios, or absolute risk differences as appropriate. NEJM has strict statistical reporting standards.
Compliance and ethics
9. Are all ethics approvals documented?
IRB/ethics committee approval with institution name and approval number in the methods. Informed consent described. DSMB (Data Safety Monitoring Board) oversight described if applicable. NEJM will not review without complete ethics documentation.
10. Have all authors declared conflicts and confirmed authorship?
NEJM permits only one corresponding author. Credit for authorship requires substantial contributions to conception, design, data acquisition, analysis, or interpretation. All conflicts of interest must be declared. NEJM has detailed financial disclosure requirements.
11. Is AI use disclosed?
As of 2025, NEJM requires disclosure of AI-assisted technologies used in manuscript preparation. If you used ChatGPT, Claude, or any AI tool, disclose it at submission.
Strategic fit
12. Have you considered a Rapid Review request?
NEJM offers Rapid Review for time-sensitive findings. If your result has immediate public health implications (pandemic data, safety signals, urgent clinical findings), you can request rapid review with a decision typically within 2 weeks and publication expedited.
For non-urgent submissions, consider whether a presubmission inquiry (brief letter describing the work) would help calibrate expectations before investing in the full submission.
The readiness shortcut
NEJM's 90% desk rejection rate means 9 out of 10 submissions are stopped before review. NEJM submission readiness check. The Manusights free scan evaluates your manuscript against NEJM's editorial standards in about 1-2 minutes.
For a paper targeting NEJM, the stakes are the highest in academic medicine. The NEJM submission readiness check provides verified citations from 500M+ live papers, figure-level feedback, and journal-specific calibration. For the most career-defining submissions, Manusights Expert Review connects you with a reviewer who has published in and reviewed for NEJM.
What gets NEJM papers desk rejected
The Executive Editor reviews every research submission personally. The desk decision is based on:
- Clinical impact too narrow. The finding matters within one specialty but does not change broad clinical practice.
- Study design limitations. An observational study making causal claims. A post-hoc analysis of a different trial. An underpowered study with borderline results.
- The result is confirmatory. Confirming what is already known, even with a larger trial, is less interesting than a finding that changes practice.
- Registration problems. Unregistered trials are returned immediately. Registration after enrollment began is flagged.
- The paper has been substantially published. Prior publication of primary results in any form (including preprints with detailed results) may affect NEJM's consideration.
How NEJM compares for pre-submission preparation
Feature | NEJM | JAMA | BMJ | |
|---|---|---|---|---|
Desk rejection | ~90% | ~80% | ~85% | ~70% |
Acceptance rate | <5% | <5% | 5 to 7% | ~7% |
Statistical review | Independent (5 consultants) | Yes | Yes | Yes |
Trial registration | Required (pre-enrollment) | Required | Required | Required |
Rapid review option | Yes | Yes (Fast Track) | No | No |
First decision | ~21 days | 21 to 28 days | ~14 days | ~17 days |
Key editorial test | Does this change clinical practice? | Global health + practice change | Clinical practice (US + international) | Clinical practice (international) |
Readiness check
Run the scan while New England Journal of Medicine's requirements are in front of you.
See how this manuscript scores against New England Journal of Medicine's requirements before you submit.
What happens after you pass the desk screen
If your paper survives the Executive Editor's triage (roughly 10% of submissions), here's the timeline:
- External review (weeks 3-6). NEJM assigns 2-3 reviewers with relevant clinical and methodological expertise. One reviewer is often a statistician or methodologist.
- Statistical review (concurrent). NEJM employs five independent statistical consultants who review every paper that advances past triage. This is unusually rigorous, most journals rely on reviewers to catch statistical issues.
- Editorial conference. The handling editor presents the paper and reviewer reports to the full editorial team. The decision is collective, not individual.
- First decision letter (week 6-8). You'll receive either a rejection with detailed reviewer comments, a request for major revision, or (rarely) a request for minor revision. Accept without revision is extremely rare.
- Revision window. If invited to revise, you typically get 8-12 weeks. The revision is re-reviewed, often by the original reviewers plus the statistical consultant.
The total timeline from submission to acceptance for successful papers is typically 4-8 months. Papers with clean revisions move faster.
In our pre-submission review work
When a manuscript is truly competitive for NEJM, the biggest issue is usually not formatting. It is whether the paper already reads like a general-medicine paper in the title, abstract, and first figure. We usually see authors underestimate how much the journal cares about immediate clinical consequence and overestimate how much editors will infer from a technically strong but narrowly framed abstract. If the practice implication is not obvious on page one, the rest of the package rarely matters.
Submit if / Think twice if
Submit if:
- the primary finding changes clinical practice beyond one specialty
- the trial registration, protocol, and primary outcome align cleanly
- the statistics section is ready for independent consultant review
- the abstract states the clinical implication in plain language
Think twice if:
- the result is strong but mainly specialty-specific
- the main claim depends on post-hoc analysis or retrospective reframing
- the protocol or registry record needs explanation before submission
- the paper still reads like a specialty-journal manuscript with a broader title added late
When is pre-submission review worth it for NEJM?
Worth the investment if:
- You are targeting NEJM where desk rejection is high
- A rejection would cost 3-6 months in resubmission cycles
- The paper is career-critical
- You want an independent assessment before submission
Skip it if:
- You have a strong track record at NEJM and know the editors
- Experienced colleagues have already reviewed the manuscript thoroughly
- Your timeline is too tight to act on the feedback
- The study has fundamental design issues needing new experiments
Next steps after reading this
If you are evaluating this journal for submission, the most productive next step is a quick readiness check. A NEJM submission readiness check takes about 1-2 minutes and tells you whether your manuscript's framing, citations, and scope match what this journal's editors actually screen for.
The researchers who publish successfully at selective journals are not the ones who submit the most papers. They are the ones who identify and fix problems before submission, target the right journal the first time, and never waste 3-6 months in a review cycle that was destined to end in rejection.
Frequently asked questions
NEJM receives approximately 15,000 to 17,000 submissions annually. The acceptance rate is under 5%, and roughly 90% of submissions are desk rejected within two weeks by the Executive Editor without external review.
Clinical impact that is too narrow for a generalist medical audience. The Executive Editor evaluates whether the finding would change how physicians across multiple specialties care for patients. Strong specialty research that only matters within one field is redirected to specialty journals.
Yes. NEJM requires prospective registration in an approved registry (ClinicalTrials.gov or WHO ICTRP) before the first participant is enrolled. Unregistered trials are returned without review, and the registration number must appear in the abstract.
The median first decision at NEJM is approximately 21 days. Desk rejections arrive within 2 weeks. Papers that advance to external peer review typically receive reviewer reports within 4 to 6 weeks.
Yes, but they face higher scrutiny than RCTs. Observational studies must address questions that cannot be answered by a trial, use robust methodology (propensity scoring, instrumental variables, or similar approaches), and have large enough sample sizes that the results are convincing without randomization.
Sources
Final step
Submitting to New England Journal of Medicine?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
Supporting reads
Conversion step
Submitting to New England Journal of Medicine?
Anthropic Privacy Partner. Zero-retention manuscript processing.